相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors
Naba Farooqui et al.
KIDNEY INTERNATIONAL REPORTS (2023)
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Yared Hailemichael et al.
CANCER CELL (2022)
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Megan L. Baker et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Laura Kalfeist et al.
CELLS (2022)
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Anne Montfort et al.
CLINICAL CANCER RESEARCH (2021)
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors
Jeffrey Aldrich et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
Fangwen Zou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
Daniel Araujo et al.
CURRENT ONCOLOGY (2021)
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
Maen Abdelrahim et al.
ONCOIMMUNOLOGY (2021)
Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report
Shohei Moriyama et al.
EUROPEAN HEART JOURNAL-CASE REPORTS (2021)
Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study
Yukio Kadokawa et al.
MOLECULAR AND CLINICAL ONCOLOGY (2021)
Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis
Jamie S. Lin et al.
ONCOIMMUNOLOGY (2021)
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Tawnie J. Braaten et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry
Rik J. Verheijden et al.
CLINICAL CANCER RESEARCH (2020)
Review: The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)
Wanhai Ke et al.
THORACIC CANCER (2020)
Severe steroid refractory gastritis induced by Nivolumab: A case report
Helene Hjorth Vindum et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2020)
Recurrent audiovestibular dysfunction and associated neurologicalimmune-relatedadverse events in a melanoma patient treated with nivolumab and ipilimumab
Jonathan S. Choi et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab
Koki Nakashima et al.
INTERNAL MEDICINE (2020)
Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
Jennifer Cautela et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome
Daniel Giglio et al.
CASE REPORTS IN ONCOLOGY (2020)
Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma
Maria Paparoupa et al.
CASE REPORTS IN GASTROENTEROLOGY (2020)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey
Candice Lesage et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Yousef R. Badran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
Houssein Safa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation
Victoria A. Chang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Blocking Tumor Necrosis Factor a Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma
Florie Bertrand et al.
CANCER RESEARCH (2015)
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development
K Takeda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)